Roche beats revenue estimates, shares slip as copycats eat into Xolair sales

ZURICH/ LONDON, Oct 22 - Swiss drugmaker Roche beat third-quarter sales expectations ​on Thursday, supported by steady demand for key medicines such as Ocrevus to buy time as it looks abroad to restock a ‌pipeline facing looming patent expiries.

New World screwworm cases confirmed in wildlife in Texas, beef cow in New Mexico

The US Department of Agriculture said on Wednesday it confirmed ​the first detection of flesh-eating parasite New World screwworm in US wildlife in an elk in Pecos County, Texas, while New Mexico ‌authorities separately said they confirmed a case in a beef cow.

EQT to buy molecular testing firm Qiagen for $10.8 billion

Sweden's EQT will buy molecular testing company Qiagen for about €9.6 billion ($10.78 billion), the ​companies said on Wednesday, ending years of takeover speculation surrounding the Dutch firm.

Utah Apple Crunch connects kindergarteners with local farmers

About 150 kindergarteners from Canyons School District met local apple farmers at the state Capitol to learn where their food comes from and the importance of healthy eating.

New Zealand's Fisher & Paykel Healthcare hit by cyber breach

Medical device maker Fisher & Paykel Healthcare on Thursday ​said it was made aware of unauthorized and unlawful access to a subset of ‌company files and two employee email accounts.

Cencora to buy American Oncology Network in $2.4 billion deal

Drug distributor Cencora said on Wednesday it would acquire American Oncology ​Network in a deal valuing the cancer care provider at up to $2.4 billion, deepening its reach in community oncology across the United ‌States.

Abbott cuts 2026 sales growth view, plans to spin off nutrition business

Abbott Laboratories cut its 2026 sales growth forecast on Wednesday ​and said it plans to separate its nutrition business into a publicly traded company, amid costly litigation over its baby formula products.

Elevance lifts 2026 profit forecast on disciplined cost management

Elevance Health on Wednesday raised its annual profit forecast after posting ​better-than-expected quarterly results, helped by lower medical costs.

Beauty giants target 'Ozempic face' as boom in obesity drugs opens new market

Swiss skincare firm Galderma, Brazilian cosmetics group Natura and beauty giant L'Oreal are testing treatments for consumers worried about facial sagging and volume loss, looking to capitalise on a growing market tied to ​the boom in obesity drugs.